Skip to main content
Clinical Trials/PACTR202011894723114
PACTR202011894723114
Other
Phase 4

Pharmacodynamic specificities of rocuronium in sickle cell patients

ARES ULB0 sites45 target enrollmentNovember 13, 2020

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Genetic Diseases
Sponsor
ARES ULB
Enrollment
45
Status
Other
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 13, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ARES ULB

Eligibility Criteria

Inclusion Criteria

  • Sickle cell patients requiring elective laparoscopic surgery (defined as patients who did not require emergency surgery within 12 hours following admission to the hospital), as well as non\-sickle cell patients matched to the same types of surgical procedures for the control group were included. After informed consent from patients, we included twenty two 22” patients in the sickle cell patients and twenty three 23 patients in the control group. There were three 03” main indications for surgery: cholecystectomy, appendectomy, and splenectomy.

Exclusion Criteria

  • We did not include patients age less than 18 and over 55 years, pregnancy, emergency surgery or surgery within the 12 hours following admission to the ward, predicted difficult ventilation or intubation, body mass index (BMI) over 30, known muscular disease, liver disease and in control group chronic renal disease and ASA 3 patients.

Outcomes

Primary Outcomes

Not specified

Similar Trials